Tags

Type your tag names separated by a space and hit enter

Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Biol Blood Marrow Transplant. 2013 Jan; 19(1):150-5.BB

Abstract

We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response).

Authors+Show Affiliations

Department of Hematology, Service des Maladies du sang, INSERM U892, PRES LUNAM, University Hospital, Angers, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22960387

Citation

Tanguy-Schmidt, Aline, et al. "Long-term Follow-up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients With De Novo Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: a GRAALL Study." Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, vol. 19, no. 1, 2013, pp. 150-5.
Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013;19(1):150-5.
Tanguy-Schmidt, A., Rousselot, P., Chalandon, Y., Cayuela, J. M., Hayette, S., Vekemans, M. C., Escoffre, M., Huguet, F., Réa, D., Delannoy, A., Cahn, J. Y., Vernant, J. P., Ifrah, N., Dombret, H., & Thomas, X. (2013). Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation, 19(1), 150-5. https://doi.org/10.1016/j.bbmt.2012.08.021
Tanguy-Schmidt A, et al. Long-term Follow-up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients With De Novo Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: a GRAALL Study. Biol Blood Marrow Transplant. 2013;19(1):150-5. PubMed PMID: 22960387.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. AU - Tanguy-Schmidt,Aline, AU - Rousselot,Philippe, AU - Chalandon,Yves, AU - Cayuela,Jean-Michel, AU - Hayette,Sandrine, AU - Vekemans,Marie-Christiane, AU - Escoffre,Martine, AU - Huguet,Françoise, AU - Réa,Delphine, AU - Delannoy,André, AU - Cahn,Jean-Yves, AU - Vernant,Jean-Paul, AU - Ifrah,Norbert, AU - Dombret,Hervé, AU - Thomas,Xavier, Y1 - 2012/09/06/ PY - 2012/04/16/received PY - 2012/08/29/accepted PY - 2012/9/11/entrez PY - 2012/9/11/pubmed PY - 2013/6/8/medline SP - 150 EP - 5 JF - Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation JO - Biol Blood Marrow Transplant VL - 19 IS - 1 N2 - We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response). SN - 1523-6536 UR - https://www.unboundmedicine.com/medline/citation/22960387/Long_term_follow_up_of_the_imatinib_GRAAPH_2003_study_in_newly_diagnosed_patients_with_de_novo_Philadelphia_chromosome_positive_acute_lymphoblastic_leukemia:_a_GRAALL_study_ DB - PRIME DP - Unbound Medicine ER -